Market Place
Sourcing Support
Alterity Therapeutics Releases Q3 FY26 Cash Flow Report
30 Apr 2026 //
GLOBENEWSWIRE
Alterity Pharma Appoints Ann Cunningham To Board Of Directors
19 Apr 2026 //
FIRSTWORD PHARMA
Alterity Pharma Names Daniel O. Claassen Chief Medical Advisor
04 Mar 2026 //
GLOBENEWSWIRE
Q4 FY25 Quarterly Cash Flow Report - Appendix 4C
30 Jul 2025 //
GLOBENEWSWIRE
Alterity Therapeutics to Provide Corporate Update
23 Jun 2025 //
GLOBENEWSWIRE
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
24 Jan 2025 //
GLOBENEWSWIRE
Alterity Appoints Abby Macnish Niven as Company Secretary
19 Nov 2024 //
GLOBENEWSWIRE
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
31 Oct 2024 //
GLOBENEWSWIRE
Alterity Appoints Abby Macnish Niven As CFO
30 Sep 2024 //
GLOBENEWSWIRE
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
31 Jul 2024 //
GLOBENEWSWIRE
Alterity Therapeutics to Present at MST Financial Webinar
24 Jul 2024 //
GLOBENEWSWIRE
Alterity Reports Positive Interim Data For ATH434 In MSA Trial
17 Jul 2024 //
GLOBENEWSWIRE
Alterity Webcast On New bioMUSE Natural History Study Data
29 May 2024 //
GLOBENEWSWIRE
Alterity DMC Recommends Continuing Phase 2 Trial
08 May 2024 //
GLOBENEWSWIRE
Alterity Therapeutics Receives a A$3.9M R&D Tax Incentive Refund
26 Mar 2024 //
GLOBENEWSWIRE
Alterity to Present New Data at the American Academy of Neurology Meeting
20 Feb 2024 //
GLOBENEWSWIRE
Alterity Phase 2 Data Monitoring Committee Recommends Continuing Trial
06 Feb 2024 //
GLOBENEWSWIRE
Alterity Therapeutics to Participate in ShareCafe Hidden Gems Webinar This Week
29 Jan 2024 //
GLOBENEWSWIRE
Alterity Therapeutics Issues Shareholder Letter
22 Jan 2024 //
GLOBENEWSWIRE
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
20 Dec 2023 //
GLOBENEWSWIRE
Alterity Therapeutics Reports Positive Efficacy Data for ATH434
04 Dec 2023 //
GLOBENEWSWIRE
Alterity Therapeutics Announces Presentation of Novel Biomarker Data
27 Nov 2023 //
GLOBENEWSWIRE
Alterity Announces Presentation of Data Demonstrating Novel Mechanisms of ATH434
16 Nov 2023 //
GLOBENEWSWIRE
Appendix 4C “ Q1 FY24 Quarterly Cash Flow Report
30 Oct 2023 //
GLOBENEWSWIRE
Alterity Presents New Data on MSA, a Rare Parkinsonian Disorder
31 Aug 2023 //
GLOBENEWSWIRE
Alterity Granted Composition of Matter Patent for Neurodegenerative Disease
23 Aug 2023 //
GLOBENEWSWIRE
Alterity Receives a $4.74 million Research & Development Tax Incentive Refund
15 Aug 2023 //
GLOBENEWSWIRE
Appendix 4C Q4 FY23 Quarterly Cash Flow Report
31 Jul 2023 //
GLOBENEWSWIRE
Alterity PII Data Monitoring Committee Recommends Continuing Trial as Planned
26 Jul 2023 //
GLOBENEWSWIRE
Alterity initiates new Phase II advanced MSA therapy trial
30 May 2023 //
CLINICAL TRIALS ARENA
Alterity Therapeutics CEO David Stamler to Present at SHARE Series Management
19 May 2023 //
GLOBENEWSWIRE
Appendix 4C “ Q3 FY23 Quarterly Cash Flow Report
10 May 2023 //
GLOBENEWSWIRE
Alterity doses first participant in Australia in Phase II trial of MSA
10 May 2023 //
CLINICAL TRIALS ARENA
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE
26 Apr 2023 //
GLOBENEWSWIRE
Alterity Therapeutics Enrolls First Patient in ATH434 Phase 2 Trial
04 Apr 2023 //
GLOBENEWSWIRE
Alterity Therapeutics Announces Granting of New Composition of Matter Patent
14 Mar 2023 //
GLOBENEWSWIRE
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Trial
08 Mar 2023 //
GLOBENEWSWIRE
Alterity Receives Regulatory Authorization to Proceed with ATH434 PII Trial
16 Feb 2023 //
GLOBENEWSWIRE
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report
31 Jan 2023 //
PR NEWSWIRE
Alterity`s ATH434 Prevents Loss of Brain Cells in Parkinson`s Disease Model
30 Jan 2023 //
GLOBENEWSWIRE
Alterity Launches ATH434 PII Trial in Italy for the Treatment of MSA
25 Jan 2023 //
GLOBENEWSWIRE
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in United States
09 Jan 2023 //
PR NEWSWIRE
Alterity Announces Presentation of Data from bioMUSE Natural History Study
07 Nov 2022 //
PRNEWSWIRE
Alterity Announces Presentation of MRI Data from bioMUSE Natural History Study
26 Oct 2022 //
PRNEWSWIRE
Alterity Therapeutics obtains approval in Australia to begin MSA therapy
14 Oct 2022 //
CLINICALTRIALSARENA
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia
13 Oct 2022 //
PRNEWSWIRE
Alterity Receives U.S. FDA Approval for Investigational NDA for ATH434
20 Sep 2022 //
PRNEWSWIRE
Alterity begins Phase II multiple system atrophy therapy trial in UK
25 Aug 2022 //
CLINICALTRIALSARENA
Alterity Therapeutics Launches ATH434 PII Trial for MSA
25 Aug 2022 //
PRNEWSWIRE
Alterity Begins Dosing in ATH434 PII Trial in Multiple System Atrophy
06 Jul 2022 //
PRNEWSWIRE
Alterity obtains authorisation in Italy for PII trial of MSA therapy
24 Jun 2022 //
CLINICALTRIALSARENA
Alterity initiates Phase II multiple system atrophy therapy trial
03 Jun 2022 //
CLINICALTRIALSARENA
Alterity Tx Launches ATH434 PII Trial for Multiple System Atrophy
02 Jun 2022 //
PRNEWSWIRE
Alterity Announces Regulatory Authorization to Proceed with ATH434 PII Trial
27 Apr 2022 //
PRNEWSWIRE
Alterity Tx to Present bioMUSE Data at AAN Annual Meeting
06 Apr 2022 //
PRNEWSWIRE
Alterity Therapeutics Announces Presentation of ATH434 at ASCO
09 Nov 2021 //
PRNEWSWIRE
Alterity Announces New Publications Providing Further Evidence ATH434
04 Nov 2021 //
PRNEWSWIRE
Alterity Therapeutics Announces Expanded ATH434 Ph2 Clinical Development Program
19 Oct 2021 //
PRNEWSWIRE
Alterity Announces Presentation of Biomarker Data at the IPMD Congress 2021
20 Sep 2021 //
PRNEWSWIRE
Alterity Therapeutics Announces Publication of Data on ATH434
15 Jul 2021 //
PR NEWSWIRE
